Esperion Therapeutics (ESPR) Convertible Debt (2020 - 2025)
Historic Convertible Debt for Esperion Therapeutics (ESPR) over the last 6 years, with Q3 2025 value amounting to $97.1 million.
- Esperion Therapeutics' Convertible Debt fell 6305.82% to $97.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.1 million, marking a year-over-year decrease of 6305.82%. This contributed to the annual value of $96.7 million for FY2024, which is 6301.74% down from last year.
- According to the latest figures from Q3 2025, Esperion Therapeutics' Convertible Debt is $97.1 million, which was down 6305.82% from $97.0 million recorded in Q2 2025.
- Esperion Therapeutics' 5-year Convertible Debt high stood at $272.5 million for Q3 2021, and its period low was $96.7 million during Q4 2024.
- Its 5-year average for Convertible Debt is $227.9 million, with a median of $260.3 million in 2023.
- Per our database at Business Quant, Esperion Therapeutics' Convertible Debt soared by 4399.53% in 2021 and then plummeted by 6305.82% in 2025.
- Esperion Therapeutics' Convertible Debt (Quarter) stood at $258.3 million in 2021, then grew by 0.63% to $259.9 million in 2022, then increased by 0.65% to $261.6 million in 2023, then crashed by 63.02% to $96.7 million in 2024, then grew by 0.4% to $97.1 million in 2025.
- Its Convertible Debt stands at $97.1 million for Q3 2025, versus $97.0 million for Q2 2025 and $96.9 million for Q1 2025.